Tilray Brands (NASDAQ:TLRY) Raised to “Hold” at Wall Street Zen

Tilray Brands (NASDAQ:TLRY) was upgraded by analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a research note issued to investors on Saturday.

Several other brokerages have also issued reports on TLRY. Weiss Ratings restated a “sell (d-)” rating on shares of Tilray Brands in a research note on Wednesday, January 21st. Zacks Research raised shares of Tilray Brands from a “strong sell” rating to a “hold” rating in a report on Wednesday, February 11th. Roth Mkm lowered their price objective on Tilray Brands from $20.00 to $10.00 and set a “neutral” rating on the stock in a research report on Tuesday, January 20th. ATB Cormark Capital Markets raised shares of Tilray Brands from a “strong sell” rating to a “hold” rating in a research note on Wednesday, December 10th. Finally, Canaccord Genuity Group started coverage on Tilray Brands in a research note on Tuesday, January 27th. They set a “hold” rating for the company. One equities research analyst has rated the stock with a Buy rating, six have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $13.33.

Tilray Brands Stock Performance

Shares of TLRY stock opened at $6.21 on Friday. Tilray Brands has a one year low of $3.51 and a one year high of $23.20. The company has a debt-to-equity ratio of 0.19, a current ratio of 2.81 and a quick ratio of 1.72. The firm has a 50-day moving average of $7.83 and a 200-day moving average of $10.51. The company has a market cap of $723.53 million, a P/E ratio of -0.28 and a beta of 1.95.

Tilray Brands (NASDAQ:TLRY) last posted its quarterly earnings data on Thursday, January 8th. The company reported ($0.02) EPS for the quarter, beating the consensus estimate of ($0.14) by $0.12. The firm had revenue of $217.51 million during the quarter, compared to analyst estimates of $211.15 million. Tilray Brands had a negative net margin of 251.69% and a negative return on equity of 6.35%. During the same quarter last year, the business posted ($0.03) EPS. Equities research analysts forecast that Tilray Brands will post -0.2 EPS for the current fiscal year.

Hedge Funds Weigh In On Tilray Brands

Hedge funds and other institutional investors have recently made changes to their positions in the business. Tidal Investments LLC boosted its position in Tilray Brands by 15.0% during the 2nd quarter. Tidal Investments LLC now owns 28,971,835 shares of the company’s stock valued at $12,006,000 after acquiring an additional 3,776,410 shares in the last quarter. Millennium Management LLC raised its position in shares of Tilray Brands by 281.0% in the 3rd quarter. Millennium Management LLC now owns 4,942,319 shares of the company’s stock worth $8,550,000 after purchasing an additional 3,645,060 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new position in Tilray Brands in the third quarter worth about $5,813,000. Ausdal Financial Partners Inc. bought a new position in Tilray Brands in the 2nd quarter valued at approximately $939,000. Finally, Scientech Research LLC bought a new position in shares of Tilray Brands during the third quarter valued at $1,748,000. Institutional investors own 9.35% of the company’s stock.

Tilray Brands News Summary

Here are the key news stories impacting Tilray Brands this week:

• Positive Sentiment: Tilray Medical announced its largest medical-cannabis portfolio expansion in Australia, reinforcing patient access and signaling commitment to a growth market — a revenue and patient-share catalyst for TLRY’s medical segment. Tilray Medical Announces Major Expansion of Medical Cannabis Portfolio in Australia
• Positive Sentiment: Tilray Medical, CC Pharma and 14U Pharma formed a strategic alliance with “gesund leben” and Alliance Healthcare Deutschland to accelerate market expansion in Germany — a distribution and commercialization boost for EU sales. Tilray Medical, CC Pharma, and 14U Pharma Announce Strategic Alliance
• Positive Sentiment: CEO Irwin Simon told Just Drinks the company is focused on “putting stability in place” for BrewDog — signaling management attention on operational turnaround and margin stabilization in its beverage segment. “We need to put stability in place” – Tilray Brands CEO on what lies ahead for BrewDog
• Neutral Sentiment: Market write-ups note TLRY is slipping more than the broader market in recent sessions—useful short-term context but largely descriptive of current flow rather than new fundamental news. Tilray Brands, Inc. (TLRY) Dips More Than Broader Market: What You Should Know
• Negative Sentiment: Technical analysts warn TLRY has lost a key support level and suggest downside toward ~$5 is possible if selling continues — a short-term bearish signal that can amplify downside as stops trigger. Tilray stock price has just lost a key support: is a crash to $5 coming?

Tilray Brands Company Profile

Tilray Brands, Inc is a global cannabis-lifestyle and consumer packaged goods company engaged in the cultivation, production, distribution and sale of cannabis and cannabinoid-based products. The company develops and markets a diverse portfolio of branded products spanning medical cannabis, adult-use recreational products and wellness offerings. Through state-of-the-art cultivation facilities, research and development efforts, and quality control systems, Tilray Brands aims to deliver consistent, scalable products for a range of patient and consumer needs.

Tilray’s product lineup includes cannabis flower, pre-rolls, oils and tinctures, vapes, edibles and topicals, as well as hemp-derived cannabidiol (CBD) products.